Indivior Pays Out Over Blocking US Suboxone Rivals
Company Settles For $10m Over Frustrating Buprenorphine/Naloxone Generics
Indivior has agreed to pay $10m to settle antitrust charges by the US Federal Trade Commission over its Suboxone brand.
You may also be interested in...
Commission files complaint as it reaches $50m settlement with Reckitt Benckiser.
Alvogen and Dr Reddy’s do not infringe key patents protecting Indivior’s Suboxone Film, the US Court of Appeals has confirmed. But Teva continues to fall foul of a production patent running until 2024.
As Prestige BioPharma announced plans for Phase I and Phase III trials of its PBP1502 proposed adalimumab biosimilar, as well as expected filing dates in the EU and US, the company outlined how it believes its proprietary technology will allow its Humira rival to compete aggressively on price.